Arcus Borrows $250m Despite Having $1bn In The Bank
A loan from Hercules Capital will fund Phase III development of renal cancer drug casdatifan, perhaps signaling low expectations of a Gilead opt-in.
A loan from Hercules Capital will fund Phase III development of renal cancer drug casdatifan, perhaps signaling low expectations of a Gilead opt-in.